NCT02206230已完成2 期
A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 133
- 试验地点
- 2
- 主要终点
- Overall survival
研究概览
简要总结
This study is being done to compare standard radiation therapy with hypofractionated radiation therapy for patients with newly diagnosed glioblastoma
详细描述
Hypofractionated radiation therapy (RT) in the treatment of patients with glioblastoma, 18 - 70 years of age with good performance status (ECOG 0 - 2), will be well tolerated and yield survival non-inferior to conventional fractioned RT, allowing significant abbreviation of the length of the radiation course required for these patients with limited survival. The importance of hypofractionation is, therefore, not in improving survival, but rather to shorten RT duration to improve patient comfort and convenience. This approach is pertinent given the limited life expectancy of glioblastoma and has been used in patients with prolonged survival including breast and prostate cancers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly-diagnosed, histologically proven, intracranial glioblastoma or gliosarcoma treated with maximal safe resection, which may be biopsy alone if resection is not possible.
- •History and physical examination, including neurological examination, within 14 days prior to randomization.
- •Age between 18 and 70 years, inclusive.
- •ECOG performance score 0-
- •Stable or decreasing dose of corticosteroids for at least 14 days prior to randomization (Stupp et al.).
- •Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below: (Stupp et al.)
- •ANC ≥ 1.5 x 10^9/L
- •Platelets ≥ 100 x 10^9/L
- •Serum creatinine ≤ 1.5 times ULN
- •Total serum bilirubin ≤ 1.5 times ULN
- •ALT < 3 times ULN
- •AST < 3 times ULN
- •Alkaline phosphatase < 3 times ULN
- •Patients must sign a study-specific informed consent prior to study registration and must be willing to comply with study treatment, questionnaire completion and follow-up.
排除标准
- •Recurrent or multifocal malignant gliomas. Multicentric gliomas, defined as multiple, discrete areas of enhancement on T1 weighted MRI sequences with contrast all contained within one connected region of abnormality on T2 weighted/FLAIR MRI sequences, are allowed to enroll on this study.
- •Prior invasive malignancy (except for non-melanomatous skin cancer) unless expected survival from prior malignancy is ≥ 5 years.
- •Prior head or neck RT (except for T1 glottic cancer), or systemic therapy precluding delivery of concurrent and adjuvant temozolomide
- •Treatment with any other therapeutic clinical protocol within 30 days prior to study registration or during participation in the study.
- •Severe, active co-morbidity, defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization
- •Transmural myocardial infarction within the last 6 months
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study registration
- •Any severe, active co-morbidity precluding delivery of temozolomide.
- •Women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
- •Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to temozolomide.
结局指标
主要结局
Overall survival
时间窗: Patients without an event will be censored the last time they were known to be alive. Median, 6-month, 1-year, and 2-year OS rates will be measured.
defined as the time between randomization and death due to any cause.
次要结局
- Progression-free survival (PFS)(Patients without an event will be censored at date of last follow-up for progression. Patients with no post-baseline follow-up for progression will be censored at day of randomization. Median, 6-month, 1-yr, and 2-yr PFS rates will be measured)
- Adverse events according to NCI CTCAE version 4.0 criteria.(Evaluated weekly during radiation therapy; on C1D1 and at the end of every 2 cycles of adjuvant temozolomide; post-treatment follow-up every 4 months for 2 years, then every 6 months for years 3-5 up until progression/palliative)
- Health-related quality-of-life as assessed by MMSE and EORTC QLQ-C30/QLQ-BN20 questionnaires.(Evaluated at baseline, weekly during radiation therapy, at the end of every 2 cycles of adjuvant temozolomide, and post-treatment follow-up every 4 months for 2 years, then every 6 months for years 3-5 up until progression/palliative)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate CancerNCT03274687NRG Oncology296
进行中（未招募）
不适用
Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast CarcinomaBreast CancerNCT03422003Dana-Farber Cancer Institute400
进行中（未招募）
不适用
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyNSCLCBreast CarcinomaBrain Metastases, AdultSmall-cell Lung CancerMelanomaNon-small Cell Lung CancerSCLCRenal Cell CarcinomaNCT05703269Wake Forest University Health Sciences58
已完成
2 期
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph NodesBreast CancerNCT02700386University of Colorado, Denver108
已完成
3 期
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT01459497University of Texas Southwestern Medical Center103